ZKB/CALL/ELI LILLY & CO/900/0.01/27.01.25 | Market Closed - Swiss Exchange 11:20:01 2024-06-06 EDT | ||
| 0.65 CHF | +3.17% |
|
| Current month | +12.07% | ||
| 1 month | +71.05% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-06 | 0.65 | +3.17% |
| 24-06-04 | 0.63 | -1.56% |
| 24-06-03 | 0.64 | +10.34% |
| 24-05-30 | 0.58 | +1.75% |
| 24-05-29 | 0.57 | +1.79% |
Delayed Quote Swiss Exchange
Last update June 06, 2024 at 11:20 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | ZKB |
| LLYAQZ | |
| ISIN | CH1305143500 |
| Date issued | 2024-03-08 |
| Strike | 900 $ |
| Maturity | 2025-01-27 (235 Days) |
| Parity | 100 : 1 |
| Emission price | 0.72 CHF |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.65 CHF |
|---|---|
| Lowest since issue | 0.33 CHF |
| Spread | 0.01 CHF |
| Spread % | 1.52% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
837.3
USD
Average target price
853.8
USD
Spread / Average Target
+1.97%
- Stock Market
- Warrants
- LLYAQZ Warrant
